Details of the Drug Reposition

General Information of This Drug (ID: DMQCXSG)

• Drug Name: Avexitide (DMQCXSG)
• Synonyms: Avexitide; Avexitide [USAN]; Exendin (9-39); Exendin 9-39; Exendin(9-39)amide; Exendin-(9-39); 5313W10MYT; UNII-5313W10MYT; Exendin 3 (heloderma horridum), 1-de-L-histidine-2-de-L-serine-3-de-L-aspartic acid-4-deglycine-5-de-L-threonine-6-de-L-phenylalanine-7-de-L-threonine-8-de-L-serine-; Exendin-3 (9-39) amide; exendin(9-39); AVEXITIDE [INN]; Exendin (9-39) amide; GTPL1138; EXENDIN (9-39) [MI]; DB14806; 9-39-EXENDIN 4 (HELODERMA SUSPECTUM); ASP-LEU-SER-LYS-GLN-MET-GLU-GLU-GLU-ALA-VAL-ARG-LEU-PHE-LLE-GLU-TRP-LEU-LYS-ASN-GIY-GIY-PRO-SER-SER-GIY-ALA-PRO-PRO-PRO-SER-NH2; L-SERINAMIDE, L-.ALPHA.-ASPARTYL-L-LEUCYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-METHIONYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ALANYL-L-VALYL-L-ARGINYL-L-LEUCYL-L-PHENYLALANYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-TRYPTOPHYL-L-LEUCYL-L-LYSYL-L-ASPARAGINYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-ALANYL-L-PROLYL-L-PROLYL-L-PROLYL-
• Drug Type: Peptide

Information on Drug Reposition of This Drug

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hypoglycemia	DISRCKR7	5A41	Phase 2	[1]
Congenital hyperinsulinism	DIS1EPQ3	5A4Y	Phase 2	[2]

References

• [1] ClinicalTrials.gov (NCT03373435) A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04652479) A Phase 2, Open-Label, Cross-over Study to Assess the Safety and Efficacy of Avexitide in Acquired Hyperinsulinemic Hypoglycemia. U.S.National Institutes of Health.